Amneal announces u.s. fda filing acceptance of biologics license application (bla) for bevacizumab

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced the u.s. food and drug administration (fda) has accepted for review the biologics license application (bla) for bevacizumab, pursuant to section 351(k) pathway of the public health service act, and with a standard review goal date in the second quarter of 2022 according to the bsufa (biosimilar user fee act). the biosimilar was developed in collaboration with mabxience, a sp
AMRX Ratings Summary
AMRX Quant Ranking